摩根士丹利发表报告指，由于私有化在即，中国中药(00570.HK) 自二月交易公布以来的交易模式主要受交易可能性的影响。8月和9月的正面事件例如管理层评论及两个先决条件的进展令股价更接近收购价。因此，目前股价与4.6元的发售价间的差价有限，只有6%。而该股近期的反弹反映出投资者对交易实现的信心。该行指，考虑到中药配方颗粒的进一步减价，该行将公司2024至2030年盈利预测下调3至15%。评级由“...
Source Link摩根士丹利发表报告指，由于私有化在即，中国中药(00570.HK) 自二月交易公布以来的交易模式主要受交易可能性的影响。8月和9月的正面事件例如管理层评论及两个先决条件的进展令股价更接近收购价。因此，目前股价与4.6元的发售价间的差价有限，只有6%。而该股近期的反弹反映出投资者对交易实现的信心。该行指，考虑到中药配方颗粒的进一步减价，该行将公司2024至2030年盈利预测下调3至15%。评级由“...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.